Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence

NCT05205746 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS CoV 2 Infection

Interventions

BIOLOGICAL: Recombinant NDV Vectored Vaccine for SARS-CoV-2
BIOLOGICAL: Placebo

Sponsor

Laboratorio Avi-Mex, S.A. de C.V.

Collaborators

[object Object]
[object Object]